Passa al contenuto
Merck
Tutte le immagini(4)

Documenti

E6888

Sigma-Aldrich

Enalapril maleate salt

powder, ≥98% (TLC)

Sinonimo/i:

(S)-N-[1-(Ethoxycarbonyl)-3-phenylpropyl]-Ala-Pro maleate salt

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Formula empirica (notazione di Hill):
C20H28N2O5 · C4H4O4
Numero CAS:
Peso molecolare:
492.52
Numero CE:
Codice UNSPSC:
12352200
ID PubChem:
NACRES:
NA.77

Saggio

≥98% (TLC)

Forma fisica

powder

Colore

white to off-white

Solubilità

methanol: ≥50 mg/mL, clear, colorless to yellow

Ideatore

Merck & Co., Inc., Kenilworth, NJ, U.S.

Stringa SMILE

C[C@@H](C(N1[C@H](C(O)=O)CCC1)=O)N[C@H](CC(OCC)=O)CCC2=CC=CC=C2.O=C(OO)/C=C\C(O)=O

InChI

1S/C21H30N2O5.C4H4O5/c1-3-28-19(24)14-17(12-11-16-8-5-4-6-9-16)22-15(2)20(25)23-13-7-10-18(23)21(26)27;5-3(6)1-2-4(7)9-8/h4-6,8-9,15,17-18,22H,3,7,10-14H2,1-2H3,(H,26,27);1-2,8H,(H,5,6)/b;2-1-/t15-,17-,18-;/m0./s1
UQKQUZOIQFOJOI-KJHLASMFSA-N

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Descrizione generale

Enalapril is an angiotensin-converting enzyme inhibitor. It is used to treat heart failure and high blood pressure.

Applicazioni

Enalapril maleate salt has been used:
  • to reduce albumin excretion rate (AER) and glomerular lesions
  • to examine the effects of enalapril pre-treatment on myocardial injury
  • to investigate its efficacious doses and schedules for mitigation of radiation lung injury

Azioni biochim/fisiol

A long-acting angiotensin-converting enzyme inhibitor.

Caratteristiche e vantaggi

This compound is a featured product for ADME Tox research. Click here to discover more featured ADME Tox products. Learn more about bioactive small molecules for other areas of research at sigma.com/discover-bsm.
This compound was developed by Merck & Co., Inc., Kenilworth, NJ, U.S.. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Pittogrammi

Health hazard

Avvertenze

Warning

Indicazioni di pericolo

Classi di pericolo

Repr. 2

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Dispositivi di protezione individuale

Eyeshields, Gloves, type N95 (US)


Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 8

1 of 8

Vinpocetine ≥98%, solid

Sigma-Aldrich

V6383

Vinpocetine

Ramipril ≥98% (HPLC)

Sigma-Aldrich

R0404

Ramipril

Losartan Potassium

Supelco

61188

Losartan Potassium

Enalaprilat analytical standard

Supelco

43301

Enalaprilat

Trandolapril ≥98% (HPLC), white, powder

Sigma-Aldrich

T4827

Trandolapril

HOE 140 ≥94%

Sigma-Aldrich

H157

HOE 140

Chor Ho Jo et al.
Electrolyte & blood pressure : E & BP, 18(2), 31-39 (2021-01-08)
Puromycin aminonucleoside (PA) can induce nephrotic syndrome in rats, and proteinuria is an important mediator of tubulointerstitial injury in glomerulopathy. We assumed that glomerular proteinuria may affect tubular function, such as urinary concentration, and investigated whether a urinary concentration defect
Lufei Hu et al.
PloS one, 17(1), e0261000-e0261000 (2022-01-28)
Diabetic nephropathy is associated with endothelial dysfunction and oxidative stress, in which the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate (NO-sGC-cGMP) signaling pathway is impaired. We hypothesize that sGC stimulator Compound 1 can enhance NO signaling, reduce proteinuria in a diabetic
Urinary peptidomics provides a noninvasive humanized readout of diabetic nephropathy in mice
Klein J, et al.
Kidney International, 90(5), 1045-1055 (2016)
Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation
Wang G, et al.
International Journal of Molecular Sciences, 38(5), 1463-1473 (2016)
Guang Liu et al.
American journal of physiology. Renal physiology, 319(4), F697-F711 (2020-09-01)
Praliciguat, a clinical-stage soluble guanylate cyclase (sGC) stimulator, increases cGMP via the nitric oxide-sGC pathway. Praliciguat has been shown to be renoprotective in rodent models of hypertensive nephropathy and renal fibrosis. In the present study, praliciguat alone and in combination

Articoli

Discover Bioactive Small Molecules for ADME/Tox

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.